Tags : (rituximab-abbs)

Biosimilars Biotech

Celltrion’s Truxima (rituximab-abbs) Receives FDA’s Approval for Three on-Hodgkin’s Lymphoma

Shots: The approval is based on non-inferiority data demonstrating biosimilarity in pharmacology, immunogenicity, clinical efficacy with safety, potency and purity when compared to reference medicine (rituxan) Truxima is a mAb, indicated and approved in three indications i.e. r/r, low-grade or follicular, CD20-positive, B-cell NHL, 1L patients with CD20-positive B-cell NHL and 1L Non-progressing low-grade CD20-positive […]Read More